Ezetimibe and the risk of new-onset type 2 diabetes: a systematic review and meta-analysis

Background Statins reduce cardiovascular risk but may increase new-onset type 2 diabetes mellitus (NO-T2DM). Ezetimibe, a cholesterol absorption inhibitor, is often added to statins to improve lipid control, yet its impact on NO-T2DM remains uncertain.Objective This systematic review evaluated moder...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Areej S. Albawa’neh, Mais N. Alqasrawi, Zeina N. Al-Mahayri, Amal Albawaana, Gamila Ahmed, Rami H. Al-Rifai, Bassam R. Ali
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Taylor & Francis Group 2025-12-01
Edice:	Annals of Medicine
Témata:	Statins ezetimibe T2DM diabetes mellitus lipids
On-line přístup:	https://www.tandfonline.com/doi/10.1080/07853890.2025.2594355
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!